Background Pain and fatigue are among the most debilitating symptoms of systemic sclerosis (SSc), severely impairing quality ...

The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience ...

Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...

Objective To study the pathophysiological differences of EGPA and IgG 4-related disease (RD) by clarifying their clinical, pathological and immunological features. Methods Clinical and pathological ...

Objectives To evaluate the diagnostic utility of optical coherence tomography angiography (OCTA)-derived biomarkers in patients with giant cell arteritis (GCA) and to advance the pathophysiological ...

Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib ...

Gout is one of the most severe and frequent rheumatic diseases. Clinical manifestations of gout arise from uric acid crystal deposition in the musculoskeletal tissue. At high concentrations of uric ...

Objective To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses ...

Objectives This study aimed to evaluate the long-term safety and efficacy profiles of ozoralizumab in patients with rheumatoid arthritis (RA) from the OHZORA, NATSUZORA and HOSHIZORA trials. Methods ...

Objectives To explore characteristics and treatment of patients with rheumatoid arthritis (RA) with invasive fungal infections (IFIs) and to describe infection details and outcome. Methods IFIs ...

Objective Clinical observation suggests that vascular activation and autoimmunity precede remodelling of the extracellular matrix (ECM) in systemic sclerosis (SSc). We challenge this paradigm by ...

Macrophage activation syndrome (MAS) is a subtype of haemophagocytic lymphohistiocytosis (HLH), and a well-described complication of systemic juvenile idiopathic arthritis (SJIA), triggered by disease ...